Clinical investigation of cefuzonam in patients over 65 years old with biliary tract infections

Naoaki Tanno, Masaru Koizumi, Tooru Shimosegawa, Takayoshi Toyota, Hitoshi Rin, Keisuke Oota, Mizuo Kobari, Akihiko Ishida, Atsushi Miyazaki, Waichi Sato, Masahide Abe, Horoyoshi Onodera, Akio Yago, Tadahiro Suzuki, Hidetoshi Hirakawa, Tooru Matsuda, Shinichi Iketani, Norihiro Suzuki, Kouki Eda

Research output: Contribution to journalArticlepeer-review

Abstract

We performed a multicenter clinical trial of cefuzonam (CZON) to evaluate its efficacy and safety in 21 patients over 65 years old with biliary tract infections. CZON was intravenously administered (2~4 g/day) to 11 patients with acute cholecystitis, 8 patients with acute cholangitis and 2 patients with acute cholecystitis plus cholangitis. Seven patients were concurrently treated by biliary drainage. The following results were obtained. 1) The overall clinical efficacy rate was 100%. 2) Bacteriological efficacy was assessed in 4 patients. Bacterial eradication was observed in 3 patients, and bacterial decrease was seen in 1 patient. 3) The clinical adverse effect, skin eruption, which was observed in only 1 patient (5%), was mild and transient. 4) The clinical usefulness rate was 100%. 5) The concentration of CZON in the bile 1 hour after intravenous injection of 1 g of the drug was very favorable, 588. 8±276. 9μg/ml (mean in 5 patients). The serum concentration of CZON 1 hour after intravenous injection of 1 g of the drug was 64.7±16.3μg/ml. We conclude that CZON is very effective and safe in patients over 65 years old with biliary tract infections.

Original languageEnglish
Pages (from-to)1104-1112
Number of pages9
JournalChemotherapy
Volume41
Issue number10
DOIs
Publication statusPublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint

Dive into the research topics of 'Clinical investigation of cefuzonam in patients over 65 years old with biliary tract infections'. Together they form a unique fingerprint.

Cite this